Biogen and Neurimmune Announce Option Exercise for Alzheimer’s Disease Investigational Treatment Aducanumab

Transaction increases profit potential of aducanumab for Biogen and provides near-term capital to Neurimmune CAMBRIDGE, Mass. & ZURICH–(BUSINESS WIRE)–Biogen (Nasdaq: BIIB) and Neurimmune announced today that Biogen has exercised its option to further reduce the previously negotiated royalty rates payable

New SPINRAZA® (nusinersen) Data Unveiled at AAN Annual Meeting Show Continued Improvement in Motor Function for Broad Age Range and Survival Benefit for Infants

SHINE data illustrates SPINRAZA’s longer-term benefits for infantile-onset SMA, including improvements in motor function and increased event-free survival in participants followed for nearly three years Additional findings show that later-onset SMA patients treated with SPINRAZA walked longer distances while experiencing

Biogen and Ionis Expand Strategic Collaboration to Develop Drug Candidates for a Broad Range of Neurological Diseases

Transaction builds upon the productive collaboration that produced SPINRAZA® as well as two antisense drug candidates currently in the clinic, with the potential to advance up to seven more drug candidates to the clinic within the next two years The antisense platform developed by Ionis is an established and validated gene-based therapeutic modality,

Biogen Builds on Its 40-Year Legacy in Neuroscience with Presentation of Research from Its Portfolio of Medicines and Investigational Programs for Neurodegenerative Diseases

New data underscore benefits of SPINRAZA ® (nusinersen) across broad spinal muscular atrophy (SMA) populations and include longer-term efficacy and safety assessments from the SHINE study Data from Biogen’s multiple sclerosis (MS) research programs include results from clinical investigation of a potential